AstraZeneca to present ‘more than’ 100 abstracts regarding SCLC and MBV at ASCO

AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology ASCO Annual Meeting, May 31 to June 4. “More than 100 abstracts will feature 25 approved and potential new medicines across the Company’s diverse oncology portfolio and pipeline, including two late-breaking plenary presentations, a special late-breaking abstract session presentation and 15 oral presentations. Highlights include: LAURA Phase III trial of TAGRISSO or osimertinib, in unresectable, Stage III epidermal growth factor receptor-mutated or EGFRm, non-small cell lung cancer NSCLC after chemoradiotherapy CRT, Plenary LBA4.